CES Unveiled in Amsterdam Highlights Tech Improving Lives
The Consumer Technology Association (CTA) ® today made several announcements at CES Unveiled in Amsterdam, an official CES® 2020 preview event. Executives, influential media and prominent industry influencers gathered at the record-breaking event to celebrate the latest European innovations and experience what to expect at CES 2020.
CTA announced that eight companies from the Netherlands and the surrounding region were announced as CES 2020 Innovation Honorees. Best of Innovation honorees include Dutch company Hydraloop Systems BV in the Sustainability, Eco-Design & Smart Energy category and British company Valerann in the Smart Cities category.
“Europe is a hotbed for innovation consistently driving our industry forward and we saw the promise and power of technology at CES Unveiled in Amsterdam,” said Karen Chupka, EVP, CES. “CES 2020 will showcase the most innovative tech from Europe that truly has the potential to make people’s lives better.”
The remaining honorees will be revealed at CES Unveiled in Paris on Oct. 22., 2019, and CES Unveiled New York on Nov. 7, 2019. Honorees will be posted online at CES.tech starting Nov. 7, 2019 and many will showcase their winning products at CES 2020, Jan. 7-10, in Las Vegas.
In its third year, CES Unveiled in Amsterdam set records by selling out exhibit space and bringing together more than 1,500 attendees from nearly 50 countries. The event also featured government and industry leaders from the Netherlands and surrounding regions including, Pete Hoekstra, U.S. Ambassador to the Netherlands; Mona Keijzer, Netherlands State Secretary for Economic Affairs and Climate Policy; Femke Halsema, Mayor of Amsterdam; and Corinne Vigreux, co-founder of TomTom and founder of CODAM.
Europe welcomed more than 16,000 attendees to CES 2019 and continues to lead innovation by example. The European Union had a strong presence at CES Unveiled in Amsterdam, featuring leaders including, Katerina Borunska, Policy Officer, European Commission; Hubert Cottogni, Director, Head of Mandate Management, European Investment Fund; and Els Sweeney-Bindels, Head of EIB Amsterdam Office, European Investment Bank. CES Unveiled promotes the continued value it shares with Europe through partnerships across government, business and research.
TechLeap.NL also announced their new visual identity and the 50 startups they are bringing to CES 2020 as part of Eureka Park. HRH Prince Constantijn van Oranje, Special Envoy at TechLeap.NL, also discussed why CES is important for Dutch startups and why he is working to make the Netherlands the best place for tomorrow’s leaders in technology.
Owned and produced by CTA, CES 2020, the world’s largest and most influential tech event, will run Jan. 7-10, 2020, in Las Vegas, NV and provide access to the most transformative tech across various marketplaces, such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, vehicles, digital health and more. Industry leaders and rising stars will come together again to pioneer future innovation driving the ever-evolving tech industry.
Registration for CES 2020 is now open. For the latest exhibitor news and show announcements, visit CES.tech.
About CES:
CES® is the largest, most influential tech event in the world – the proving ground for breakthrough technologies and global innovators. This is where the world's biggest brands do business and meet new partners, and the sharpest innovators hit the stage. Owned and produced by the Consumer Technology Association (CTA)®, CES features every aspect of the tech sector. Learn more at CES.tech and follow CES on social.
About Consumer Technology Association:
As North America’s largest technology trade association, CTA® is the tech sector. Our members are the world’s leading innovators – from startups to global brands – helping support more than 18 million American jobs. CTA owns and produces CES® – the largest, most influential tech event on the planet. Find us at CTA.tech. Follow us @CTAtech.
UPCOMING EVENTS
-
CES Unveiled in Paris
October 22 – Paris, France -
Consumer Technology Hall of Fame
November 6, 2019 – New York, NY -
CES Unveiled New York
November 7 – New York, NY -
CES Unveiled Las Vegas
January 5, 2020 – Las Vegas, NV -
CES 2020
January 7-10, 2020 – Las Vegas, NV
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191017005692/en/
Contact information
Justin Siraj
703-907-7415
jsiraj@CTA.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 04:41:00 EET | Press release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 03:15:00 EET | Press release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 23:10:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerstone of IonQ’s global strategy,” said Niccolo de Masi, Chairman and CEO of IonQ. “QuantumBasel continues to be a critical innovation node for our company as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
